The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Bispecific T-cell engagers in the treatment of myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the milieu of emerging data surrounding bispecific T-cell engagers (BiTEs) for the treatment of multiple myeloma. Dr Martin highlights the investigation of BiTEs targeting different antigens and their differences in efficacy and side effect profile. Dr Martin goes on to discuss the clinical pros and cons of using different myeloma targets, such as the ability to switch targets when a patient becomes refractory. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK
